SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--FDB (First Databank), the leading provider of clinical drug knowledge that helps improve medication-related decisions and patient outcomes, today announced that it will present a poster that recommends appropriate medication pediatric dosing at the 23rd Annual Pediatric Pharmacy Advocacy Group (PPAG) Meeting and 2014 Pediatric Pharmacy Conference, April 30 – May 4, 2014, in Nashville, Tennessee. The poster summarizes consensus recommendations derived from an evidenced-based review by a panel of independent pediatric drug dosing experts from eight leading children’s hospitals. FDB sponsored and directed the work of the expert panel.
The poster entitled, “Evaluation and Recommendations for 200+ Commonly Prescribed Pediatric Drugs Where Product Dosing Labeling Information is Lacking,” summarizes findings from the panel’s evaluation of a total of 924 pediatric dosing records. The key focus of the expert dosing panel was to review and recommend clinically acceptable minimum/maximum dosing recommendations based upon age and clinical evidence along with expert opinion.
With the goal to increase pediatric patient safety related to medication dose range screening for prescribing clinicians, the panel recommended new consensus-based limits for medications where no age-specific FDA-approved labeling information exists. For example, intravenous infliximab previously had dosing limits for 6 years to adult age; the expert panel recommendation extended dosing limit guidance of infliximab at 3-10 mg/kg for 1 year to adult age. A total of 668 dosing records are being changed in FDB MedKnowledge™ as a result of the panel’s recommendations.
“There are a multitude of challenges in developing accurate guidelines for pediatric drug dosing,” said Karl Matuszewski, vice president of clinical and editorial knowledge base services, FDB, who, along with other drug dosing experts at FDB, co-led and directed the work of the expert panel. “Our hope is that the new content in pediatric drug dosing recommended by the panel will greatly enhance the effectiveness of pediatric computerized physician order entry and dose checking, decrease alert fatigue and improve patient care for this important population.”
FDB’s drug knowledge and clinical screening information is utilized by thousands of hospitals, payers and pharmacies across the United States, as well as by the majority of state Medicaid agencies, CMS, the Department of Defense, and the Veterans Administration.
FDB (First Databank), part of the Hearst Health network, is the leading provider of drug knowledge that helps healthcare professionals make precise medication-related decisions. With thousands of customers worldwide, FDB enables our information system developer partners to deliver a wide range of valuable, useful, and differentiated solutions. As the company that virtually launched the medication decision support category, we offer more than three decades of experience in transforming drug knowledge into actionable, targeted, and effective solutions that improve patient safety and healthcare outcomes. For a complete look at our solutions and services please visit www.fdbhealth.com or follow us on Twitter and LinkedIn.
About Hearst Health
FDB is part of the Hearst Health network, which also includes Zynx Health, MCG (formerly Milliman Care Guidelines) and Homecare Homebase. The mission of the Hearst Health network is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Each year in the U.S., care guidance from the Hearst Health network reaches 76% of discharged patients, 133 million insured individuals, 20 million home health visits, 1.88 billion retail pharmacy prescriptions and 3.26 billion prescription claims. Extensions of the Hearst Health network include Hearst Health Ventures and the Hearst Health Innovation Lab.
© 2014 First Databank, Inc. Part of the Hearst Health network. All trademarks mentioned herein are the properties of their respective owners.